World Federation of Hemophilia/LinkedIn
Oct 30, 2025, 06:57
For People on Emicizumab, the Use of a aPCC Raises Critical Clinical Questions
World Federation of Hemophilia shared a post on LinkedIn:
“For people on emicizumab, the use of activated prothrombin complex concentrate (aPCC) raises critical clinical questions. A new article bridges evidence with real-world practice to guide safer, smarter care decisions.”
Title: Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice
Authors: Robert F. Sidonio, Jr., Guy Young, Carmen Escuriola Ettingshausen, Johnny Mahlangu, Margareth C. Ozelo, Alok Srivastava, Jerzy Windyga, Hye–Youn Lee, Aurelia Lelli, Steven W. Pipe

Read full article here.
Stay informed with Hemostasis Today.
activated prothrombin complex concentrate (aPCC)
Alok Srivastava
Aurelia Lelli
Carmen Escuriola Ettingshausen
Emicizumab
Guy Young
Health
Hematology
Hemostasis
Hemostasis Today
Hye–Youn Lee
Jerzy Windyga
Johnny Mahlangu
Jr.
Margareth C. Ozelo
Medicine
Robert F. Sidonio
rpth
Steven W. Pipe
World Federation of Hemophilia
-
Sep 19, 2026, 09:48Kanchal Mahesh: A First Step Into the World of Research
-
Sep 19, 2026, 09:45Pablo Corral: Is the Classic Model of Hepatic Cholesterol Homeostasis Incomplete?
-
Sep 19, 2026, 09:38Faheema Hasan: ASH’s 2026 Guidelines on the Diagnosis of Iron Deficiency is out!
-
Sep 19, 2026, 09:37Omar Adwan: Rule of Three in Complete Blood Count
-
Sep 19, 2026, 09:26Kerry Taylor-Smith: Cold or Flu? – How to Tell the Difference
-
Sep 19, 2026, 09:13Stand with Bleeding Disorder Patients This World Patient Safety Day – WFH
-
Sep 19, 2026, 09:09Stefanie Dimmeler: How the Lymphatic System Shapes Heart Aging
-
Sep 19, 2026, 08:51Zia Ullah Shah: Advancing Early Diagnosis of Wilson Disease With AI and Biomarkers
-
Sep 19, 2026, 03:15Paulus Kirchhof: Europe’s Safe Hearts Plan to Reduce Cardiovascular Mortality